PDCD1 and autoimmune disease: However, it has also been reported that tumor treatment by inhibiting the PD-1/PD-L1 signaling pathway was likely to cause immune imbalance, resulting in autoimmune diseases, such as multiple sclerosis, inflammatory bowel disease, Hashimoto’s thyroiditis, and rheumatoid arthritis (19, 20).